Metastatic Clear Cell Renal Cell Carcinoma (RCC) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

 Renal cell carcinoma (RCC), the 8th most common malignancy affecting adults, accounts for between 3% and 4% of new cancer cases in the United States. The classic clinical presentation of flank pain, hematuria, and a palpable flank mass are comparatively uncommon (5–10% of cases). However, clinical symptomatology may be relatively nonspecific. For example, anorexia, tiredness, weight loss, or fever of unknown origin. The clear cell histologic subtype remains the most common, representing approximately 70% of all renal tumors and an even more significant proportion of patients with metastatic RCC (>80%). The vast majority of clear cell RCC is characterized by biallelic loss of function of the von Hippel Lindau (VHL) tumor suppressor gene. Prognosis is generally reflected in staging severity, with the lower-stage disease associated with longer survival rates. The prediction is noticeably adversely affected by the spread of the tumor beyond the renal fascia and into the retroperitoneum (TNM T3a and higher) · The more common sites of metastases as reported in stage IV disease (TNM T4 or N1+ M1 disease) are the lung (69%), bone (43%), liver (34%), lymph nodes (22%), adrenal gland (19%), brain (7%), and thyroid, skin, and bladder (< 1% each)

·       The prevalence of patients present with localized disease. However, approximately one-third present with locally advanced or metastatic disease, and up to 30% of patients undergoing surgical resection will experience recurrent disease.

 

Thelansis’s “Metastatic Clear Cell Renal Cell Carcinoma (RCC) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Metastatic Clear Cell Renal Cell Carcinoma (RCC) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

 

KOLs insights of Metastatic Clear Cell Renal Cell Carcinoma (RCC) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Metastatic Clear Cell Renal Cell Carcinoma (RCC) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Metastatic Clear Cell Renal Cell Carcinoma (RCC) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Tags: Metastatic Clear Cell Renal Cell Carcinoma (RCC), Metastatic Clear Cell Renal Cell Carcinoma (RCC) market outlook, Metastatic Clear Cell Renal Cell Carcinoma (RCC) competitive landscape, Metastatic Clear Cell Renal Cell Carcinoma (RCC) market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)